NCT01757665已完成不适用
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform (COMMENCE)
Edwards Lifesciences64 个研究点 分布在 3 个国家目标入组 777 人开始时间: 2012年12月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 777
- 试验地点
- 64
- 主要终点
- Subjects With Structural Valve Deterioration
研究概览
简要总结
The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.
详细描述
Multicenter, prospective, single arm trial - Up to seven hundred (700) aortic valve replacement (AVR) subjects and up to one hundred seventy-five (175) mitral valve replacement (MVR) subjects at up to forty (40) clinical sites will be enrolled. The trial will include male and female patients, 18 years or older, requiring replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic or mitral valve. Patients will be followed and assessed after implant for up to 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligibility Criteria:
- •Inclusion Criteria:
- •Is 18 years or older
- •Provides written informed consent prior to trial procedures
- •Agrees to attend all follow-up assessments for up to 5 years and is willing to comply with specified follow-up evaluations at clinical investigational sites that are participating in the COMMENCE trial and/or obtain the protocol-specified diagnostic tests at centers that are under the same IRB or the same healthcare system
- •Diagnosed with aortic or mitral valve disease requiring valve replacement based on pre- operative evaluation
- •Scheduled to undergo planned aortic or mitral valve replacement with or without concomitant bypass surgery
- •Scheduled to undergo planned aortic valve replacement with or without resection and replacement of the ascending aorta from the sinotubular junction and without the need for circulatory arrest for hemi arch or arch replacement
排除标准
- •A subject meeting any of the following criteria shall be excluded:
- •Requires emergency surgery
- •Requires planned multiple valve replacement/ repair (with the exception of mitral valve replacement with tricuspid valve repair)
- •Has prior valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ
- •Requires a surgical procedure outside of the cardiac area (e.g. vascular bypass)
- •Requires surgical replacement of the aortic root
- •Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months to the scheduled aortic or mitral valve replacement surgery
- •Has renal insufficiency as determined by creatinine (S-Cr) level ≥ 2.5 mg/dL or end -stage renal disease requiring chronic dialysis at screening visit
- •Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months (180 days) prior to planned valve surgery
- •Has acute myocardial infarction (MI) within 30 days prior to planned valve surgery
- •Has presence of non-cardiac disease limiting life expectancy to less than 12 months
- •Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM)
- •Diagnosed with abnormal calcium metabolism and hyperparathyroidism
- •Exhibits left ventricular ejection fraction ≤ 20% as validated by diagnostic procedure prior to planned valve surgery
- •Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation
- •Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery
- •Documented leukopenia (WBC < 3.5x 10³/μL), acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L) or thrombocytopenia (platelet count < 50x 10³/μL) accompanied by history of bleeding diathesis and coagulopathy
- •Has prior organ transplant or is currently an organ transplant candidate
- •Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
- •Was previously implanted with trial device (Model 11000A or Model 11000M)
- •Pregnant (female subject of childbearing potential only), lactating or planning to become pregnant during the duration of participation in trial
- •Currently incarcerated or unable to give voluntary informed consent
- •Documented history of substance (drug or alcohol) abuse within the last 5 years prior to implant
- •Requires concomitant left ventricular assist device (LVAD) placement
结局指标
主要结局
Subjects With Structural Valve Deterioration
时间窗: 1 Year Post Implant
The rate of implanted subjects that experience structural valve deterioration (SVD) of the trial valve by the time of the post operative day (POD) 390 follow-up visit. Structural valve deterioration includes dysfunction or deterioration intrinsic to the valve. Examples of SVD includes complications such as wear, fracture, calcification, leaflet tear.
次要结局
- Percentage of Subjects With Early Adverse Events(Events occuring within 30 days of procedure)
- Percentage of Late Adverse Events Divided by Late Patient Years(Events occurring >= 31 days and up through 3 years post-implant)
研究者
研究点 (64)
Loading locations...
相似试验
进行中（未招募）
不适用
SMall Annuli Randomized To Evolut™ or SAPIEN™ TrialSymptomatic Aortic StenosisAortic Valve StenosisAortic Valve ReplacementNCT04722250Medtronic Cardiovascular1,103
已完成
不适用
Sterile Single-use vs Reused Polyvinylchloride Catheter For Intermittent Catheterization In Neurogenic BladderNeurogenic Bladder Due to Spina Bifida (Disorder)NCT03424499Hospital Universitario Dr. Jose E. Gonzalez113
招募中
不适用
Sterile Allogeneic Spongioflex® Allograft as Partial Meniscal Replacement After Incomplete Meniscal LossMeniscus LesionNCT06376422Sven Behrendt40
终止
不适用
Safety and Effectiveness Study of Perceval S Valve for Extended CE MarkAortic Valve ReplacementNCT01368666Corcym S.r.l658
招募中
不适用
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuREAortic StenosisNCT06777368Medtronic Cardiovascular225